Dr. Delev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
836 W Wellington Ave
Room 7304
Chicago, IL 60657Phone+1 773-296-7046
Education & Training
- Johns Hopkins UniversityFellowship, Rheumatology, 2009 - 2011
- Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 2006 - 2009
- Medical University of Sofia FOMClass of 2003
Certifications & Licensure
- VA State Medical License 2012 - 2024
- NJ State Medical License 2012 - 2023
- IL State Medical License 2006 - 2014
- MD State Medical License 2012 - 2014
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.Eric F Morand, Marilyn Pike, J Merrill, Ronald F van Vollenhoven, Victoria P Werth
Expert Opinion on Investigational Drugs. 2024-05-01 - 78 citationsDeucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Eric Morand, Marilyn Pike, Joan T Merrill, Ronald van Vollenhoven, Victoria P Werth
Arthritis & Rheumatology. 2023-02-01 - 14 citationsBiological impact of iberdomide in patients with active systemic lupus erythematosus.Peter E Lipsky, Ronald van Vollenhoven, Thomas Dörner, Victoria P Werth, Joan T Merrill
Annals of the Rheumatic Diseases. 2022-04-27
Press Mentions
- New Lupus Partnership with FDA Aims to End Drug Trials’ History of FailureMarch 29th, 2023
Industry Relationships
- Executive Medical Director, BMS
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: